Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors

Plain-language summary

This study examines the genetic landscape in women with metastatic ovarian cancer before and during treatment with PARP inhibitors, using samples of buccal cells, bone marrow, and blood. It enrolls women in complete or partial remission after surgery who are eligible for oral PARP inhibitors as first-line or maintenance therapy. It is a non-phase study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

European Institute of Oncology

Intervention

buccal cells, bone marrow cells, peripheral blood cells, bone marrow biopsy

Start date

10/2/2020

Estimated completion

4/30/2028

Countries

Italy

Related genes

Locations

• Milan, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Women with advanced ovarian cancer in complete or partial remission after surgery and eligible to oral PARP inhibitors as first line in association to chemotherapy or as maintenance therapy.

Exclusion Criteria:

* Presence of blood cell count abnormalities before PARP inhibitor treatment;
* Bone marrow infiltration by EOC cells.